Besides, SOX30 is regarded as a prognostic biomarker in terminal ovarian cancer patients (9); elevated SOX30 expression is regarded as a predictor of better survival among non-small cell lung cancer patients (10). Here, SOX30 is linked to non-small cell lung carcinoma.